IGLC2 and neoplasm: For IgA+IGLC2+ plasma cells, allograft rejection, interferon‐alpha response, interferon‐gamma response, and inflammatory response were enhanced in the tumor‐derived cells, indicating the involvement in promoting inflammatory responses in tumors.